Innovent Bio Reports Novel Bi-Specific is Effective in AMD Trial

Suzhou Innovent reported its bi-specific fusion protein was effective in patients with neovascular age-related macular degeneration (nAMD). The Phase I trial showed the 31 participants were able to read six additional letters in an eye exam following a single treatment. Innovent's IBI302 is a first-in-class recombinant human anti-VEGF and anti-complement bi-specific molecule. The complement system is part of the innate immune response. Although VEGF drugs have revolutionized treatment for AMD, some patients develop resistance to them over time. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.